Details of the Researcher

PHOTO

Ken Saijo
Section
Tohoku University Hospital
Job title
Senior Assistant Professor
Degree

  • 博士（医学）（東北大学）

Education 1

  • 東北大学大学院　医学部　医学系研究科

    2008/04 - 2012/03

Research Interests 2

  • chemotherapy

  • clinical oncology

Research Areas 1

  • Life sciences / Tumor diagnostics and therapeutics /

Awards 6

  1. 医学系研究助成（がん領域（基礎））

    2023/11　武田科学振興財団

  2. 第33回黒川利雄がん研究基金

    2022/06　公益財団法人 宮城県対がん協会

  3. 東北大学プロミネントリサーチフェロー

    2022/02　東北大学

  4. 治験実施若手奨励者

    2021/12　東北大学病院

  5. 研究奨励賞

    2015/06　日本癌分子標的治療学会

  6. ESMO-Asia 2015 in Singapore トラベルグラント

    2015　日本臨床腫瘍学会

Show all ︎Show 5

Papers 65

  1. A retrospective study of pembrolizumab plus chemotherapy for head and neck cancer patients: influence of response in combination phase on subsequent maintenance phase. International-journal

    Ken Saijo, Hiroo Imai, Yuki Kasahara, Ryunosuke Numakura, Reio Ueta, Keiju Sasaki, Yuya Yoshida, Sho Umegaki, Sakura Taniguchi, Kota Ouchi, Keigo Komine, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka

    Discover oncology　16　(1)　479-479　2025/04/07

    DOI： 10.1007/s12672-025-02256-1 　

    More details Close

    BACKGROUND: Pembrolizumab plus chemotherapy is considered one of the standard treatment regimens for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). The regimen comprises up to 6 cycles of pembrolizumab-chemotherapy combination phase and subsequent pembrolizumab maintenance phase. Pembrolizumab-chemotherapy combination confers high response rate, creating favorable conditions for pembrolizumab maintenance phase. This study examined the influence of response in the combination phase on the efficacy in subsequent maintenance phase. METHODS: We retrospectively reviewed the medical records of patients with R/M HNSCC who received pembrolizumab plus chemotherapy as a first-line regimen at Tohoku University Hospital, Sendai, Japan. Progression-free survival (PFS) was analyzed when it was divided into the combination and maintenance phases. RESULTS: A total of 44 patients were enrolled. The best overall response was observed in the combination phase in all patients, and the overall response rate was 46.3%. The median PFS was 5.8 months (95% CI: 4.9-7.1). PFS differed significantly according to the response. When analyzed separately, the PFS only in the maintenance phase differed depending on the response of partial response (PR) or stable disease (SD). There was no difference in the number of chemotherapy cycles between patients with PR and SD. Univariate and multivariate analyses showed that the response in the combination phase was significantly associated with PFS in the maintenance phase. CONCLUSION: In the pembrolizumab plus chemotherapy regimen for patients with R/M HNSCC, the response in the combination phase may be associated with PFS in the maintenance phase.

  2. Coexisting germline variants of MLH1 and MSH6 in a patient with Lynch syndrome who had uterine and ovarian cancer. International-journal

    Sho Umegaki, Masanobu Takahashi, Junko Hasegawa-Minato, Maako Kawamura, Sakura Taniguchi, Keigo Komine, Hideki Tokunaga, Kota Ouchi, Hiroo Imai, Ken Saijo, Hidekazu Shirota, Fumiyoshi Fujishima, Muneaki Shimada, Yoko Aoki, Chikashi Ishioka

    International cancer conference journal　14　(2)　171-176　2025/04

    DOI： 10.1007/s13691-025-00753-2 　

    More details Close

    Lynch syndrome is an autosomal dominant disorder caused by a heterozygous pathogenic germline variant in mismatch repair (MMR) genes including MLH1, MSH2, MSH6, PMS2, and EPCAM. This disease often causes a familial cluster of patients with malignant tumors. In this report, we describe a 37-year-old woman who presented with endometrioid carcinoma in the ovary and uterine corpus associated with Lynch syndrome. She carried two germline pathogenic variants, a recurrently reported MLH1 c.2250C > G (p.Tyr750*) and a previously unreported MSH6 c.2385del (p.Ile795Metfs*15). The tumor cells showed microsatellite instability. Immunohistochemistry for the endometrial tumor showed decreased MLH1 expression, loss of PMS2 expression, retained MSH2 expression, and loss of MSH6 expression, which suggests that both variants impair each protein stability and thus cause MMR deficiency. Whether these variants were inherited from her parents or occurred de novo was unknown. The tumor cells had somatic variants BRCA1 c.1016del and BRCA2 c.36dupT that might be due to secondary mutation by MMR deficiency. The use of an immune checkpoint inhibitor pembrolizumab resulted in durable partial response of metastatic lung tumors. This case reminds clinicians of the rare possibility of multiple germline variants in MMR genes in individuals with Lynch syndrome.

  3. Regional Differences in the Frequency of BRCA1 and BRCA2 Variants in Northeastern Japan: A Cohort Study. International-journal

    Hidekazu Shirota, Akimitsu Miyake, Maako Kawamura, Shuhei Suzuki, Kensuke Saito, Jun Yasuda, Hiroyuki Shibata, Motonobu Saito, Takeshi Iwaya, Hiroshi Tada, Muneaki Shimada, Naoki Kawamorita, Masayuki Kanamori, Eisaku Miyauchi, Hidetaka Niizuma, Tomoyuki Iwasaki, Yuki Kasahara, Hiroo Imai, Ken Saijo, Keigo Komine, Masanobu Takahashi, Tetsuya Niihori, Yoko Aoki, Toru Furukawa, Gen Tamiya, Chikashi Ishioka

    Cancer medicine　14　(8)　e70443　2025/04

    DOI： 10.1002/cam4.70443 　

    More details Close

    BACKGROUND: Germline mutations in BRCA1/2 are known to cause hereditary tumors in the breast, ovary, and other organs. With the widespread adoption of comprehensive diagnostics, including comprehensive genomic profiling (CGP) tests for solid tumors, many patients with BRCA1/2 variants have been identified. METHODS: In this study, we extracted and analyzed cases of BRCA1/2 variants that were presumed to be germline, which were repeatedly detected using the CGP test for solid tumors in northeastern Japan. The frequencies of BRCA1/2 variants in regional areas were compared with those of healthy individuals or nationwide cancer cohorts to investigate regional distribution. RESULTS: Our findings revealed regional disparities in BRCA1/2 pathogenic germline variants, while variants of unknown significance (VUS) showed no such differences. The regional distribution of BRCA1 and BRCA2 variants showed distinct patterns: pathogenic variants of BRCA1 exhibited regional differences and were less prevalent compared to VUS, whereas BRCA2 variants, including both pathogenic variants and VUS, did not exhibit such clear regional localization. This discrepancy in regional distribution between BRCA1 and BRCA2 variants could be attributed to factors such as the diversity of the genome, gender differences, and cancer types. CONCLUSIONS: These results highlight the importance of considering regional differences in comparative cohort studies, particularly in assessing the differential extension of mutations in pathogenic changes and VUS. Moreover, a presumption of pathogenicity variants would need to be discussed at the regional level.

  4. Impact of genetic mutations on prognosis and chemotherapy efficacy in advanced appendiceal carcinoma: insights from the nationwide Japanese comprehensive genomic profiling test database.

    Sakura Hiraide Taniguchi, Masanobu Takahashi, Shih-Wei Chiu, Keigo Komine, Shonosuke Wakayama, Ryunosuke Numakura, Yuya Yoshida, Yuki Kasahara, Kota Ouchi, Hiroo Imai, Ken Saijo, Hidekazu Shirota, Chikashi Ishioka

    International journal of clinical oncology　2025/02/28

    DOI： 10.1007/s10147-025-02724-2 　

    More details Close

    BACKGROUND: Appendiceal carcinoma (AC) is a rare malignancy and has distinct genomic features, but their impact on prognosis and chemotherapy efficacy requires further investigation. METHODS: This retrospective study analyzed patients with advanced AC from the Japanese nationwide comprehensive genomic profiling test database, the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database, focusing on genetic alterations and their associations with clinical outcomes. RESULTS: Of the 314 patients, the histological types Queryincluded adenocarcinoma (Ad) (51.9%), mucinous adenocarcinoma (MAd) (30.3%), goblet cell adenocarcinoma (12.4%), and signet-ring cell adenocarcinoma (5.4%). The most common mutations were KRAS (52.5%), TP53 (49.4%), SMAD4 (18.8%), and GNAS (17.2%). KRAS mutations were most frequent in MAd (68.4%) and Ad (58.9%), whereas TP53 mutations were mostly prevalent in Ad (62.6%). We classified patients into molecular subtypes based on the presence of mutations and analyzed differences in overall survival (OS) by molecular subtype. Patients with TP53-mutant (mut) dominant tumors (all TP53-mut) and KRAS-mut focused tumors (TP53-wild-type (wt)/GNAS-wt/KRAS-mut/any SMAD4) showed a poorer median OS compared with those with GNAS-mut focused tumors (TP53-wt/GNAS-mut/any KRAS /any SMAD4) (median 47.4 and 37.5 months vs. not reached; p = 0.01 and p = 0.01, respectively). TP53 mutation was associated with poor time to treatment failure and OS with the oxaliplatin-based regimen for first-line chemotherapy. CONCLUSIONS: This study suggested that the genetic mutations influenced the prognosis and chemotherapy efficacy in AC.

  5. Immune-Modified Glasgow Prognostic Score Predicts Therapeutic Effect of Pembrolizumab in Recurrent and Metastatic Head and Neck Cancer. International-journal

    Natsuko Ueda, Masashi Kuroki, Hirofumi Shibata, Manato Matsubara, Saki Akita, Tatsuhiko Yamada, Rina Kato, Ryota Iinuma, Ryo Kawaura, Hiroshi Okuda, Kosuke Terazawa, Kenichi Mori, Ken Saijo, Toshimitsu Ohashi, Takenori Ogawa

    Cancers　16　(23)　2024/12/03

    DOI： 10.3390/cancers16234056 　

    More details Close

    BACKGROUND: Previously, we proposed that the immune-modified Glasgow Prognostic Score (imGPS), which adds the lymphocyte count to the mGPS, is helpful as a prognostic marker for patients with head and neck squamous cell carcinoma. In this study, we investigated the imGPS as a marker for the therapeutic effect of pembrolizumab in treating recurrent and metastatic head and neck cancer (RMHNC). METHODS: This study included RMHNC patients who were treated with pembrolizumab from December 2019 to April 2024. ALB, CRP, lymphocyte counts, neutrophil-to-lymphocyte ratios (NLRs), mGPSs, and imGPSs were extracted as biomarkers, and the response rate and prognosis were analyzed for each. RESULTS: A total of 54 patients were enrolled. Lymphocyte counts were correlated with the overall response rates (ORRs) (p = 0.0082). Although the mGPS did not show significant differences in ORRs, imGPSs revealed a significant difference (p = 0.013). CRP, ALB, and lymphocyte counts were correlated with overall survival (OS) and/or progression-free survival (PFS). NLRs, mGPSs, and imGPSs were also correlated with OS and/or PFS, with imGPSs showing the greatest area under the curve (OS; AUC = 0.795, PFS; AUC = 0.754). CONCLUSIONS: This study demonstrates that the imGPS is an excellent predictive marker for the therapeutic effect and prognosis of pembrolizumab for RMHNC. The imGPS can be employed with daily blood tests, highlighting the potential to forecast the impact of the ICI with high reliability.

  6. Pretreatment neutrophil-lymphocyte ratio as a prognostic factor in recurrent/metastatic head and neck cancer treated with pembrolizumab. International-journal

    Yuki Kasahara, Ken Saijo, Reio Ueta, Ryunosuke Numakura, Keiju Sasaki, Yuya Yoshida, Sakura Taniguchi, Kota Ouchi, Keigo Komine, Hiroo Imai, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka

    Scientific reports　14　(1)　28255-28255　2024/11/16

    DOI： 10.1038/s41598-024-79130-7 　

    More details Close

    Pembrolizumab-containing regimens are the standard first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). The neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein-to-albumin ratio (CAR) have been reported to be important prognostic factors in a variety of carcinomas, but none have been investigated in combination with pembrolizumab and chemotherapy or in first-line treatment. Seventy-four patients with R/M HNSCC received pembrolizumab-containing regimens at Tohoku University Hospital, Sendai, Japan, from April 2020 to March 2023. Patient characteristics, tumor response, overall survival (OS), progression-free survival (PFS), and laboratory findings were reviewed. Associations between NLR, CAR, and survival outcomes were analyzed. The 1-year OS and 1-year PFS rates were 60.4% and 18.1%, respectively. The disease control rate was 66.2%. In multivariate analysis, low NLR (< 5) was significantly associated with better OS and PFS. NLR may be a predictive factor for OS and PFS in patients with R/M HNSCC treated with a pembrolizumab-containing regimen.

  7. Nivolumab-induced Thrombotic Thrombocytopenic Purpura in Patients with Gastric Tube Cancer.

    Yuya Yoshida, Sakura Toriyabe, Hiroo Imai, Keiju Sasaki, Yuki Kasahara, Kota Ouchi, Ken Saijo, Koichi Onodera, Chikashi Ishioka

    Internal medicine (Tokyo, Japan)　63　(19)　2667-2671　2024/10/01

    DOI： 10.2169/internalmedicine.2931-23 　

    More details Close

    Recently, immune checkpoint inhibitors (ICIs) have been used to treat several cancer types. ICIs have been reported to cause a wide variety of immune-related adverse events, including endocrine, neurologic, gastrointestinal, and cutaneous disorders. Thrombotic thrombocytopenic purpura (TTP) is an autoimmune hematologic disorder characterized by the presence of autoantibodies against a disintegrin and metalloprotease with thrombospondin-1, member 13. Several previous cases of TTP were thought to have been caused by ICI treatment. We herein report a rare case of TTP that developed after long-term treatment with an ICI (nivolumab) for gastric tube cancer.

  8. Carrier-free nano-prodrugs for minimally invasive cancer therapy Peer-reviewed

    Keita Tanita, Yoshitaka Koseki, Sanjay Kumar, Farsai Taemaitree, Asuka Mizutani, Hirotaka Nakatsuji, Ryuju Suzuki, Anh Thi Ngoc Dao, Fumiyoshi Fujishima, Hiroshi Tada, Takanori Ishida, Ken Saijo, Chikashi Ishioka, Hitoshi Kasai

    Nanoscale　16　(32)　15256-15264　2024/07/26

    Publisher: Royal Society of Chemistry (RSC)

    DOI： 10.1039/d4nr01763c 　

    ISSN： 2040-3364

    eISSN： 2040-3372

    More details Close

    SNC4DC, a dimer of SN-38 derivatives, has been synthesized. SNC4DC nanoparticles called nano-prodrugs are internalized into the cell and dissociate, and the active SN-38 is released after reduction of the S–S bond in the presence of GSH occurs.

  9. Correlation between Efficacy and Cardiovascular Adverse Events in Patients with Advanced Solid Cancer Who Received VEGF Pathway Inhibitors: Hypertension within the First Eight Weeks is Associated with Favorable Outcomes of Patients Treated with VEGF Pathway Inhibitors.

    Yuya Yoshida, Masanobu Takahashi, Keigo Komine, Sakura Taniguchi, Hideharu Yamada, Keiju Sasaki, Sho Umegaki, Yoshifumi Kawamura, Yuki Kasahara, Kota Ouchi, Hiroo Imai, Ken Saijo, Hidekazu Shirota, Noriko Takenaga, Chikashi Ishioka

    Internal medicine (Tokyo, Japan)　2024/06/13

    DOI： 10.2169/internalmedicine.3373-23 　

    More details Close

    Objective Many vascular endothelial growth factor (VEGF) pathway inhibitors are used in the treatment of patients with various advanced cancers; however, treatments induce cardiovascular adverse events (CVAEs), such as hypertension, heart failure, arrhythmia, arterial or venous embolism, and hemorrhage. Some studies have suggested a correlation between efficacy and CVAEs; however, further evidence is required. This study evaluated real-world data concerning the frequency and degree of CVAEs and possible associations between CVAEs and efficacy in such patients. Methods and Patients We analyzed CVAEs observed in 294 patients with advanced cancer who were treated with ramucirumab, regorafenib, pazopanib, sunitinib, or sorafenib. Results CVAEs of any grade and proteinuria within 8 weeks after the initiation of VEGF pathway inhibitors (early) or during the treatment period (total period) were observed in 72%-85% and 77%-92% of the patients, respectively. The progression-free survival (PFS) of patients with a CVAE of grade ≥1 in the early period was favorable compared with the PFS of those who had no CVAE (median, 4.9 vs. 3.5 months, P = 0.016, log-rank test). Furthermore, the PFS of patients with a CVAE grade ≥3 in the early period was favorable compared to that of those with CVAEs of grades 0-2. Taken together, a higher degree of CVAE was correlated with favorable patient outcomes. Conclusion This study revealed the frequency and degree of CVAEs in patients with solid cancers who received VEGF pathway inhibitors in a real-world setting and added evidence regarding the correlation between CVAEs and efficacy of VEGF pathway inhibitors.

  10. Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trial. International-journal

    Kota Ouchi, Shin Takahashi, Keiju Sasaki, Yuya Yoshida, Sakura Taniguchi, Yuki Kasahara, Keigo Komine, Hiroo Imai, Ken Saijo, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka

    International journal of colorectal disease　39　(1)　89-89　2024/06/11

    DOI： 10.1007/s00384-024-04659-y 　

    More details Close

    PURPOSE: The genome-wide DNA methylation status (GWMS) predicts of therapeutic response to anti-epidermal growth factor receptor (EGFR) antibodies in treating metastatic colorectal cancer. We verified the significance of GWMS as a predictive factor for the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer. METHODS: Clinical data were obtained from a prospective trial database, and a genome-wide DNA methylation analysis was performed. GWMS was classified into high-methylated colorectal cancer (HMCC) and low-methylated colorectal cancer (LMCC). The patients were divided into subgroups according to the treatment arm (cetuximab plus irinotecan or irinotecan alone) and GWMS, and the clinical outcomes were compared between the subgroups. RESULTS: Of the 112 patients, 58 (51.8%) were in the cetuximab plus irinotecan arm, and 54 (48.2%) were in the irinotecan arm; 47 (42.0%) were in the HMCC, and 65 (58.0%) were in the LMCC group regarding GWMS. Compared with the LMCC group, the progression-free survival (PFS) was significantly shortened in the HMCC group in the cetuximab plus irinotecan arm (median 1.4 vs. 4.1 months, p = 0.001, hazard ratio = 2.56), whereas no significant differences were observed in the irinotecan arm. A multivariate analysis showed that GWMS was an independent predictor of PFS and overall survival (OS) in the cetuximab plus irinotecan arm (p = 0.002, p = 0.005, respectively), whereas GWMS did not contribute to either PFS or OS in the irinotecan arm. CONCLUSIONS: GWMS was a predictive factor for the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer.

  11. Chylous Ascites Associated with Advanced Pancreatic Cancer That Improved with Appropriate Treatment: A Case Report. International-journal

    Hiroo Imai, Ken Saijo, Noriko Takenaga, Keigo Komine, Kota Ouchi, Yuki Kasahara, Shiori Ishikawa, Keiju Sasaki, Yuya Yoshida, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka

    Current oncology (Toronto, Ont.)　31　(3)　1477-1482　2024/03/12

    DOI： 10.3390/curroncol31030112 　

    More details Close

    Chylous ascites is a rare form of ascites with high triglyceride content arising from the thoracoabdominal lymph nodes in the peritoneal cavity due to various benign or malignant etiologies, including pancreatic cancer. During cancer chemotherapy, the accumulation of ascites can lead to the deterioration of the patient's general condition, making chemotherapy administration difficult, and resulting in a poor prognosis. We encountered a rare case of chylous ascites complicated by advanced pancreatic cancer. The patient presented with a discrepancy between the shrinkage of the pancreatic cancer and the accumulation of ascites. Therefore, we were able to promptly diagnose chylous ascites by performing biochemical tests. The patient was treated with octreotide, reportedly effective in treating chylous ascites, which rapidly improved the chylous ascites and general condition of the patient, allowing the patient to continue chemotherapy for pancreatic cancer. Therefore, physicians should consider the possibility of chylous ascites when clinically unexplained ascites are observed in patients with advanced cancer. The investigation and treatment of chylous ascites should be initiated as soon as possible.

  12. Erratum for Nivolumab-induced Thrombotic Thrombocytopenic Purpura in Patients with Gastric Tube Cancer.

    Yuya Yoshida, Sakura Toriyabe, Hiroo Imai, Keiju Sasaki, Yuki Kasahara, Kota Ouchi, Ken Saijo, Koichi Onodera, Chikashi Ishioka

    Internal medicine (Tokyo, Japan)　63　(24)　3407-3407　2024

    DOI： 10.2169/internalmedicine.E003-24 　

  13. FOLFIRI Chemotherapy for Patients With Metastatic Urachal Carcinoma. International-journal

    Sakura Hiraide Taniguchi, Keigo Komine, Noriko Takenaga, Yuya Yoshida, Keiju Sasaki, Yoshifumi Kawamura, Yuki Kasahara, Kota Ouchi, Hiroo Imai, Ken Saijo, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka

    Anticancer research　43　(12)　5699-5704　2023/12

    DOI： 10.21873/anticanres.16775 　

    More details Close

    BACKGROUND/AIM: Urachal carcinoma is a rare cancer, with limited evidence regarding systemic chemotherapy for metastatic urachal carcinoma. This study aimed to evaluate the efficacy and safety of a combination therapy of 5-fluorouracil and irinotecan (FOLFIRI) in patients with metastatic urachal carcinoma. PATIENTS AND METHODS: Patients with metastatic urachal carcinoma treated with FOLFIRI between March 2008 and April 2023 at the Department of Medical Oncology, Tohoku University Hospital, were retrospectively analyzed using medical records. RESULTS: Six patients with urachal carcinoma received FOLFIRI. The histological type was adenocarcinoma in all patients. The metastatic or recurrent sites were the peritoneum, lungs, lymph nodes, and local relapse sites. Three patients received FOLFIRI as first-line chemotherapy, and the other three received FOLFIRI as second-line chemotherapy. Two patients had only non-measurable lesions as the targets of tumor response. The best response was the stable disease or non-complete response/non-progressive disease in four patients, with a disease control rate of 67%. The median progression-free survival was 7.5 months. In two patients with ascites only as the site of metastasis, the amount of ascites and serum tumor marker levels decreased after FOLFIRI was initiated. Grade 3/4 toxicities included grade 3 neutropenia in one patient and grade 3 diarrhea in one patient. CONCLUSION: FOLFIRI has modest efficacy and good tolerability for the treatment of metastatic urachal carcinoma.

  14. Comparison of efficacy and safety between carboplatin-etoposide and cisplatin-etoposide combination therapy in patients with advanced neuroendocrine carcinoma, retrospective study. International-journal

    Hiroo Imai, Ken Saijo, Yoshifumi Kawamura, Shuto Kodera, Keigo Komine, Tomoyuki Iwasaki, Noriko Takenaga, Yuki Kasahara, Kota Ouchi, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka

    Oncology　2023/10/30

    DOI： 10.1159/000534747 　

    More details Close

    INTRODUCTION: Neuroendocrine carcinoma (NEC) is characterized by a poor prognosis and is generally treated with platinum and etoposide combination therapy as first-line chemotherapy. However, it remains uncertain whether carboplatin and etoposide combination therapy (CE) and cisplatin and etoposide combination therapy (PE) have comparable treatment efficacy. In this retrospective analysis, we compared the efficacy and safety of CE and PE in patients with NEC. METHODS: We retrospectively reviewed the patient's clinical record from 2005 to 2022 at the Department of Medical Oncology, Tohoku University Hospital. Patients who received either CE or PE were included in the study. Statistical analyses were performed using JMP Pro 16.0 (SAS Institute Inc., Cary, N.C., USA). RESULTS: A total of 104 patients were enrolled, with 73 patients assigned to the CE group and 31 patients assigned to the PE group. Statistically, the response rate, progression-free survival (PFS) time and overall survival (OS) time were 42.6%, 5.1 months (95%CI: 3.5-6.3) and 13.6 months (95%CI: 8.9-17.4), respectively, in the CE groups and 44.4%, 5.6 months (95%CI: 3.1-7.0) and 12.5 months (95%CI: 11.2-14.6), respectively, in the PE groups. There was no significant difference in treatment efficacy between the CE and the PE groups. However, the number of patients with elevated creatinine (3.35 mg/dl and 3.88 mg/dl in two patients, respectively) was significantly higher in the PE group than in the CE group. CONCLUSION: The efficacy of CE and PE in patients with NEC is comparable. However, the incidence of renal dysfunction was found to be significantly higher in the PE group than in the CE group.

  15. Antibiotics May Interfere with Nivolumab Efficacy in Patients with Head and Neck Squamous Cell Carcinoma Peer-reviewed

    Reio Ueta, Hiroo Imai, Ken Saijo, Yoshifumi Kawamura, Shuto Kodera, Keigo Komine, Kota Ouchi, Yuki Kasahara, Sakura Taniguchi, Yuya Yoshida, Keiju Sasaki, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka

    Oncology　1-8　2023/09/14

    Publisher: S. Karger AG

    DOI： 10.1159/000533860 　

    ISSN： 0030-2414

    eISSN： 1423-0232

    More details Close

    Introduction: Patients with the head and neck squamous cell carcinoma (SCC) are often treated with immune checkpoint inhibitors (ICIs). Recently, antibiotic intake was reported to lower the efficacy of ICIs in patients with several types of cancers. However, it is unclear if antibiotics affect the efficacy of ICIs in patients with head and neck SCC. We retrospectively assessed the influence of antibiotics on the treatment efficacy of nivolumab, an ICI, in patients with head and neck SCC. Methods: We reviewed the medical records of patients with head and neck SCC treated with nivolumab at the Department of Medical Oncology, Tohoku University Hospital, between 2017 and 2021. Patients who received oral or intravenous antibiotics from a month before the day of nivolumab initiation to the day of the first imaging evaluation of ICI efficacy were assigned to the antibiotic-treated group. The remaining patients were assigned to the antibiotic-untreated group. The response rate (RR), progression-free survival (PFS), and overall survival time (OS) of both groups were compared. Results: Forty-five patients were assigned to the antibiotic-treated group and 19 to the antibiotic-untreated group. The RR, median PFS, and median OS of the antibiotic-treated group were 23.7%, 3.2 months (95% confidential interval [CI]: 2.0–4.1), and 8.4 months (95% CI: 5.3–15.1) and those of the antibiotic-untreated group were 42.1%, 5.8 months (95% CI: 2.3–16.7), and 18.4 months (95% CI: 6.2–23.1), respectively. The PFS of the antibiotic-untreated group was significantly longer than that of the antibiotic-treated group. Conclusion: Our findings indicate that antibiotic treatment significantly shortens the PFS with nivolumab therapy in patients with head and neck SCC.

  16. Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens. International-journal Peer-reviewed

    Ken Saijo, Hiroo Imai, Kota Ouchi, Keiju Sasaki, Yuya Yoshida, Yoshifumi Kawamura, Sakura Taniguchi, Yuki Kasahara, Keigo Komine, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka

    Frontiers in oncology　13　1230731-1230731　2023

    DOI： 10.3389/fonc.2023.1230731 　

    More details Close

    BACKGROUND: Pembrolizumab-containing regimens are standards of care for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). The depth of response (DpR) predicts the survival of patients with several types of solid cancers; however, its association with the survival outcomes of patients with R/M HNSCC treated with pembrolizumab-containing regimens remains unclear. METHODS: This study included 66 patients with R/M HNSCC who received a pemblolizumab-containing regimen as a first-line therapy at Tohoku University Hospital, Sendai, Japan. The patients' characteristics, combined positive score, baseline tumor size, tumor response, DpR, overall survival (OS), progression-free survival (PFS), PFS2, and adverse events were reviewed. The associations between DpR and survival outcomes were analyzed. RESULTS: The 1 year-OS and 1 year-PFS rates of pembrolizumab-containing regimens were 69.4% and 24.4%, respectively. The response rate was 28.8%. The mean and median values of tumor change from baseline were 5.1% and -9.0%. In the correlation analysis, a significant negative correlation was observed between tumor change rate from baseline and survival outcomes (OS: r= -0.41, p=0.0017; PFS: r=-0.49, p<0.001). In the multivariate analysis, DpR with tumor change of ≤-45 was associated with better OS and PFS. CONCLUSION: DpR induced by pembrolizumab-containing regimens may be a predictive factor for OS and PFS in patients with R/M HNSCC.

  17. BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation

    Ken Saijo, Hiroo Imai, Hiromichi Katayama, Fumiyoshi Fujishima, Kenichi Nakamura, Yuki Kasahara, Kota Ouchi, Keigo Komine, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka

    Case Reports in Oncology　762-769　2022/08/30

    Publisher: S. Karger AG

    DOI： 10.1159/000526018 　

    eISSN： 1662-6575

    More details Close

    An 18-year-old Japanese man was diagnosed with an undifferentiated sarcoma of the spermatic cord, with multiple distant metastases to the lungs and bones. The patient received doxorubicin-based standard chemotherapy. Although the chemotherapy was effective, it induced severe adverse events, which led to treatment discontinuation. A comprehensive genomic profiling test using resected tumor tissue revealed the &lt;i&gt;BRAF&lt;/i&gt; V600E mutation. Based on the result, the patient received combination therapy with dabrafenib and trametinib. The combination therapy achieved a good response with few adverse events. However, 6.5 months later, pleural metastases and meningeal dissemination had emerged. A liquid comprehensive genomic profiling test was performed after the progression to identify the resistance mechanism, which resulted in the detection of no actionable gene alterations other than &lt;i&gt;BRAF&lt;/i&gt; V600E. This report shows that the &lt;i&gt;BRAF&lt;/i&gt; V600E mutation may be a promising therapeutic target and that resistance to the targeted therapy could also occur in soft tissue sarcoma. The significance of &lt;i&gt;BRAF&lt;/i&gt; mutations across different types of cancer should be validated, and it is necessary to apply targeted therapies and develop methods to overcome resistance based on the optimal use of comprehensive genomic profiling tests.

  18. Antibiotic Treatment Improves the Efficacy of Oxaliplatin-Based Therapy as First-Line Chemotherapy for Patients with Advanced Gastric Cancer: A Retrospective Study. International-journal

    Hiroo Imai, Ken Saijo, Keigo Komine, Reio Ueta, Ryunosuke Numakura, Shonosuke Wakayama, Sho Umegaki, Sakura Hiraide, Yoshufumi Kawamura, Yuki Kasahara, Kota Ohuchi, Masahiro Takahashi, Shin Takahashi, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka

    Cancer management and research　14　1259-1266　2022

    DOI： 10.2147/CMAR.S353432 　

    More details Close

    Purpose: One of the first-line treatment for gastric cancer patients is oxaliplatin, and the efficacy of this chemotherapeutic can be attenuated by the microbiome. In this study, we retrospectively evaluated whether treatment with antibiotics improved the efficacy of oxaliplatin-based chemotherapy in patients with advanced gastric cancer. Patients and Methods: Fifty-four patients were assigned to the antibiotic-treated group and 35 to the antibiotic-untreated group. Results: The response rate of oxaliplatin-based chemotherapy in the antibiotic-treated and antibiotic-untreated groups was 66.7% and 41.4%, respectively (p = 0.038). The median progression-free survival after oxaliplatin-based chemotherapy in the antibiotic-treated and antibiotic-untreated groups was 8.8 and 5.2 months, respectively (hazard ratio = 0.456, 95% confidence interval = 0.254-0.819; p = 0.007, Log rank test). Univariate and multivariate analyses revealed that antibiotic treatment was the only clinical parameter that correlated with the response to oxaliplatin. Conclusion: Antibiotic treatment could be used therapeutically to enhance the efficacy of oxaliplatin-based chemotherapy in patients with advanced gastric cancer.

  19. Factors related to specialized palliative care use and aggressive care at end of life in Japanese patients with advanced solid cancers: a cohort study. International-journal

    Yusuke Hiratsuka, Takayuki Oishi, Mitsunori Miyashita, Tatsuya Morita, Jennifer W Mack, Yuko Sato, Masahiro Takahashi, Keigo Komine, Ken Saijo, Chikashi Ishioka, Akira Inoue

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer　29　(12)　7805-7813　2021/12

    DOI： 10.1007/s00520-021-06364-w 　

    More details Close

    PURPOSE: This study aimed to (1) describe characteristics of aggressive care at the end of life (EOL) and (2) identify factors associated with specialized palliative care use (SPC) and aggressive care at the EOL among Japanese patients with advanced cancer. METHODS: This single-center, follow-up cohort study involved patients with advanced cancer who received chemotherapy at Tohoku University Hospital. Patients were surveyed at enrollment, and we followed clinical events for 5 years from enrollment in the study. We performed multivariate logistic regression analysis to identify independent factors related to SPC use and chemotherapy in the last month before death. RESULTS: We analyzed a total of 135 patients enrolled between January 2015 and January 2016. No patients were admitted to the intensive care unit, and few received resuscitation or ventilation. We identified no factors significantly associated with SPC use. Meanwhile, younger age (20-59 years, odds ratio [OR] 4.10; 95% confidence interval [CI] 1.30-12.91; p = 0.02) and no receipt of SPC (OR 4.32; 95% CI 1.07-17.37; p = 0.04) were associated with chemotherapy in the last month before death. CONCLUSION: Younger age and a lack of SPC were associated with chemotherapy at the EOL in patients with advanced cancer in Japan. These findings suggest that Japanese patients with advanced cancer may benefit from access to SPC.

  20. Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells. International-journal

    Yoshifumi Kawamura, Ken Saijo, Hiroo Imai, Chikashi Ishioka

    Cancer science　112　(11)　4711-4721　2021/11

    DOI： 10.1111/cas.15095 　

    More details Close

    Anaplastic thyroid cancer (ATC) is an extremely aggressive tumor associated with poor prognosis due to a lack of efficient therapies. In Japan, lenvatinib is the only drug approved for patients with ATC; however, its efficacy is limited. Therefore, novel therapeutic strategies are urgently required for patients with ATC. The present study aimed to identify compounds that enhance the antiproliferative effects of lenvatinib in ATC cells using a compound library. IRAK1/4 Inhibitor I was identified as a candidate compound. Combined treatment with lenvatinib and IRAK1/4 Inhibitor I showed synergistic antiproliferative effects via the induction of cell cycle arrest at G2/M phase in the ATC cell lines 8305C, HTC/C3, ACT-1, and 8505C. Furthermore, IRAK1/4 Inhibitor I enhanced the inhibition of ERK phosphorylation by lenvatinib in 8305C, HTC/C3, and 8505C cells. In an HTC/C3 xenograft mouse model, tumor volume was lower in the combined IRAK1/4 Inhibitor I and lenvatinib group compared with that in the vehicle control, IRAK1/4 Inhibitor I, and lenvatinib groups. IRAK1/4 Inhibitor I was identified as a promising compound that enhances the antiproliferative and antitumor effects of lenvatinib in ATC.

  21. Erratum: lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma. International-journal

    Hideharu Yamada, Masanobu Takahashi, Munenori Watanuki, Mika Watanabe, Sakura Hiraide, Ken Saijo, Keigo Komine, Chikashi Ishioka

    Oncology letters　22　(4)　698-698　2021/10

    DOI： 10.3892/ol.2021.12959 　

    More details Close

    [This corrects the article DOI: 10.3892/ol.2021.12716.].

  22. lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma

    Hideharu Yamada, Masanobu Takahashi, Munenori Watanuki, Mika Watanabe, Sakura Hiraide, Ken Saijo, Keigo Komine, Chikashi Ishioka

    Oncology Letters　21　(6)　2021/06

    DOI： 10.3892/ol.2021.12716 　

    ISSN： 1792-1074

    eISSN： 1792-1082

  23. 切除不能進行再発胃癌に対する化学療法の治療レジメンの選択とその効果に関する後ろ向き解析(A retrospective analysis of treatment sequence of chemotherapy for unresectable gastric cancer)

    高橋 信, 大内 康太, 笠原 佑記, 小峰 啓吾, 今井 源, 西條 憲, 高橋 昌宏, 城田 英和, 高橋 雅信, 石岡 千加史

    日本胃癌学会総会記事　93回　307-307　2021/03

    Publisher: (一社)日本胃癌学会

  24. LPIN1 downregulation enhances anticancer activity of the novel HDAC/PI3K dual inhibitor FK-A11. International-journal

    Hiroo Imai, Ken Saijo, Sonoko Chikamatsu, Yoshifumi Kawamura, Chikashi Ishioka

    Cancer science　112　(2)　792-802　2021/02

    DOI： 10.1111/cas.14759 　

    More details Close

    Phosphatidylinositol-3 kinase (PI3K) inhibitor and histone deacetylase (HDAC) inhibitor have been developed as potential anticancer drugs. However, the cytotoxicity of PI3K inhibitor or HDAC inhibitor alone is relatively weak. We recently developed a novel HDAC/PI3K dual inhibitor FK-A11 and confirmed its enhanced cytotoxicity when compared to that of PI3K inhibitor or HDAC inhibitor alone on several cancer cell lines. However, the in vivo antitumor activity of FK-A11 was insufficient. We conducted high-throughput RNA interfering screening and identified gene LPIN1 which enhances the cytotoxicity of FK-A11. Downregulation of LPIN1 enhanced simultaneous inhibition of HDAC and PI3K by FK-A11 and enhanced the cytotoxicity of FK-A11. Propranolol, a beta-adrenoreceptor which is also a LPIN1 inhibitor, enhanced the in vitro and in vivo cytotoxicity and antitumor effect of FK-A11. These findings should help in the development of FK-A11 as a novel HDAC/PI3K dual inhibitor.

  25. Phase ii study of the reuse of trastuzumab with docetaxel beyond progression after first-line treatment in second-line treatment for unresectable, metastatic gastric cancer (T-core1203)

    Masanobu Takahashi, Yasuhiro Sakamoto, Kazunori Otsuka, Mariko Kanbe, Hisatsugu Ohori, Yoshiaki Shindo, Hiroshi Honda, Ken Saijo, Kota Ouchi, Yasuko Murakawa, Hidekazu Takahashi, Sadayuki Kawai, Yuichi Tanaka, Takuhiro Yamaguchi, Hideki Shimodaira, Takashi Yoshioka, Chikashi Ishioka

    Tohoku Journal of Experimental Medicine　254　(1)　49-55　2021

    DOI： 10.1620/tjem.254.49 　

    ISSN： 0040-8727

    eISSN： 1349-3329

  26. Irak1/4 Inhibitor Iは甲状腺未分化癌細胞におけるlenvatinibの細胞増殖抑制効果を増強する

    川村 佳史, 西條 憲, 今井 源, 石岡 千加史

    日本癌学会総会記事　79回　OJ14-4　2020/10

    Publisher: (一社)日本癌学会

    ISSN： 0546-0476

  27. Irak1/4 Inhibitor Iは甲状腺未分化癌細胞におけるlenvatinibの細胞増殖抑制効果を増強する

    川村 佳史, 西條 憲, 今井 源, 石岡 千加史

    日本癌学会総会記事　79回　OJ14-4　2020/10

    Publisher: (一社)日本癌学会

    ISSN： 0546-0476

  28. Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei.

    Sakura Hiraide, Keigo Komine, Yuko Sato, Kota Ouchi, Hiroo Imai, Ken Saijo, Masahiro Takahashi, Shin Takahashi, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka

    International journal of clinical oncology　25　(4)　774-781　2020/04

    DOI： 10.1007/s10147-019-01592-x 　

    More details Close

    BACKGROUND: Pseudomyxoma peritonei (PMP) is a rare malignancy, and there is insufficient evidence about systemic chemotherapy for this disease. METHODS: We retrospectively evaluated the efficacy and safety of a chemotherapeutic regimen with 5-fluorouracil and oxaliplatin (modified FOLFOX6, mFOLFOX6) for patients with unresectable pseudomyxoma peritonei. Patients who received the therapy between April 2000 and February 2019 at the Department of Medical Oncology, Tohoku University Hospital, were enrolled in this study. RESULTS: Eight patients were treated with mFOLFOX6. The sites of primary tumor were appendix in six patients, ovary in a patient, and urachus in a patient. Six patients received surgery. Seven patients had histologically high-grade PMP, and one patient had low-grade PMP. The median follow-up duration was 27.2 months. All the patients had non-measurable regions as the targets of tumor response. Non-complete response or non-progressive disease was observed in seven patients, with a disease control rate of 87.5%. The median progression-free survival and overall survival were 13.0 months and 27.9 months, respectively. An obvious reduction in the symptoms was observed in two patients. Five patients experienced decline in the serum tumor markers, CEA or CA19-9. The grade 3/4 toxicity that was observed was grade 4 neutropenia in one patient and grade 3 neutropenia in two patients. CONCLUSIONS: mFOLFOX6 might be an effective and tolerable treatment option for patients with unresectable PMP. To our knowledge, this is the first case series of mFOLFOX6 in patients with unresectable PMP and the first case series of systemic chemotherapy for Asian patients with unresectable PMP.

  29. Antibiotics Improve the Treatment Efficacy of Oxaliplatin-Based but Not Irinotecan-Based Therapy in Advanced Colorectal Cancer Patients. International-journal

    Hiroo Imai, Ken Saijo, Keigo Komine, Yuya Yoshida, Keiju Sasaki, Asako Suzuki, Kota Ouchi, Masahiro Takahashi, Shin Takahashi, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka

    Journal of oncology　2020　1701326-1701326　2020

    DOI： 10.1155/2020/1701326 　

    More details Close

    Background: Oxaliplatin and irinotecan are generally used to treat advanced colorectal cancer (CRC) patients. Antibiotics improve the cytotoxicity of oxaliplatin but not irinotecan in a colon cancer cell line in vitro. This study retrospectively assessed whether antibiotics improve the treatment efficacy of oxaliplatin- but not irinotecan-based therapy in advanced CRC patients. Patients and Methods. The medical records of 220 advanced CRC patients who underwent oxaliplatin- or irinotecan-based therapy were retrospectively reviewed. The oxaliplatin and irinotecan groups were further divided into antibiotic-treated (group 1) and antibiotic-untreated (group 2) subgroups. Results: In oxaliplatin groups 1 and 2, the response rate (RR) was 58.2% and 30.2%, while the disease control rate (DCR) was 92.5% and 64.2%, respectively; the median progression-free survival (PFS) was 10.5 months (95% confidence interval (CI) = 7.5-12.2) and 7.0 months (95% CI = 17.0-26.0), respectively, and the median overall survival (OS) was 23.8 months (95% CI = 5.1-9.1) and 17.4 months (95% CI = 13.1-24.9), respectively. In irinotecan groups 1 and 2, the RR was 17.8% and 20.0%, while the DCR was 75.6% and 69.1%, respectively; the median PFS was 8.2 months (95% CI = 6.2-12.7) and 7.9 months (95% CI = 12.0-23.0), respectively, and the median OS was 16.8 months (95% CI = 5.9-10.6) and 13.1 months (95% CI = 10.4-23.7), respectively. Conclusion: To improve the treatment efficacy of oxaliplatin-based therapy in advanced CRC patients, adding antibiotics is a potential therapeutic option.

  30. DICを合併した進行胃癌患者の予後関連因子

    佐藤 悠子, 高橋 信, 大内 康太, 鈴木 朝子, 佐々木 啓寿, 吉田 裕也, 小峰 啓吾, 今井 源, 西條 憲, 高橋 昌宏, 城田 英和, 高橋 雅信, 石岡 千加史

    日本癌治療学会学術集会抄録集　57回　P71-6　2019/10

    Publisher: (一社)日本癌治療学会

  31. 切除不能虫垂癌に対する化学療法の有効性の後方視的解析

    平出 桜, 小峰 啓吾, 佐藤 悠子, 大内 康太, 今井 源, 西條 憲, 高橋 昌宏, 高橋 信, 城田 英和, 高橋 雅信, 石岡 千加史

    日本癌治療学会学術集会抄録集　57回　P75-3　2019/10

    Publisher: (一社)日本癌治療学会

  32. Successful Multidisciplinary Treatment Accomplished by Collaboration of Multiple Clinical Departments for Synchronous Quadruple Cancer

    Shunsuke Eba, Hirotsugu Notsuda, Fumihiko Hoshi, Hisashi Oishi, Yasushi Matsuda, Tetsu Sado, Masafumi Noda, Akira Sakurada, Ken Saijo, Akira Okoshi, Naoki Tanaka, Yoshinori Okada

    Kyobu geka. The Japanese journal of thoracic surgery　72　(9)　655-657　2019/09/01

    ISSN： 0021-5252

  33. A Concise Approach for Producing Optically Pure Carboxylic Acid Segments for the Synthesis of Bicyclic Depsipeptide Histone Deacetylase Inhibitors Peer-reviewed

    Koichi Narita, Noel Sayar, Ken Saijo, Chikashi Ishioka, Tadashi Katoh

    Synthesis　51　1408-1418　2019/05

  34. Therapeutic Benefits of Ipilimumab among Japanese Patients with Nivolumab-Refractory Mucosal Melanoma: A Case Series Study. Peer-reviewed

    Saijo K, Imai H, Ouchi K, Okada Y, Sato Y, Komine K, Takahashi M, Takahashi S, Shirota H, Takahashi M, Ishioka C

    Tohoku J Exp Med.　248　(1)　37-43　2019/05

    DOI： 10.1620/tjem.248.37 　

    More details Close

    The antibodies targeting programmed death 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) have provided survival benefits in patients with advanced malignant melanoma. The anti-PD-1 antibodies nivolumab and pembrolizumab are considered superior to the anti-CTLA-4 antibody ipilimumab as first-line therapy, suggesting that ipilimumab should be administered to patients with anti-PD-1 antibody-refractory melanoma in the second-line setting. However, there is limited evidence regarding the efficacy and safety of ipilimumab after disease progression on anti-PD-1 antibody therapy. Moreover, in patients with mucosal melanoma, a rare and aggressive subtype, evidence is extremely poor. This study aimed to clarify the efficacy and safety of ipilimumab among Japanese patients with nivolumab-refractory advanced mucosal melanoma. We retrospectively analyzed the seven patients with advanced mucosal melanoma who were treated with ipilimumab after disease progression on nivolumab at our hospital between September 2015 and December 2017. No patient achieved complete response or partial response to ipilimumab therapy. However, six patients achieved stable disease, and of these patients, three achieved a decline in the tumor size. All the three patients with a decline in tumor size developed grade 3 toxicity: two patients developed colitis and one patient experienced alanine aminotransferase elevation. The median progression-free survival (PFS) for prior nivolumab therapy was 148 days. The median PFS for ipilimumab therapy after disease progression with nivolumab was 193 days. The median overall survival was 661 days. In conclusion, although even partial response was undetectable with ipilimumab therapy, ipilimumab could produce additional PFS among nivolumab-refractory advanced mucosal melanoma patients.

  35. 2種のタキサン系薬剤を使用する際の、2種目のタキサン系薬剤の効果予測因子

    今井 源, 西條 憲, 小峰 啓吾, 川村 佳史, 平出 桜, 梅垣 翔, 高橋 昌宏, 高橋 信, 高橋 雅信, 石岡 千加史

    日本内科学会雑誌　108　(Suppl.)　256-256　2019/02

    Publisher: (一社)日本内科学会

    ISSN： 0021-5384

    eISSN： 1883-2083

  36. Antibiotic therapy augments the efficacy of gemcitabine-containing regimens for advanced cancer: a retrospective study. International-journal

    Hiroo Imai, Ken Saijo, Keigo Komine, Yasufumi Otsuki, Kota Ohuchi, Yuko Sato, Akira Okita, Masahiro Takahashi, Shin Takahashi, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka

    Cancer management and research　11　7953-7965　2019

    DOI： 10.2147/CMAR.S215697 　

    More details Close

    Background: The addition of antibiotics reportedly augments the efficacy of gemcitabine (GEM) in tumor-bearing mice. However, whether this phenomenon is also observed in cancer patients remains unclear. In the present study, we aimed to assess whether antibiotics for treatment or prevention of infection augments treatment efficacies of GEM-containing regimens in patients with any type of cancer. Methods: Medical records of patients diagnosed with cancer histopathologically and treated with GEM-containing regimens (n=169) were retrospectively reviewed. Patients were assigned into two groups: antibiotics-untreated group (patients who were treated with GEM-containing regimens but without antibiotics) and antibiotics-treated group (patients who were treated with GEM-containing regimens plus antibiotics). Response rates, progression-free survival (PFS) time, and overall survival (OS) time were analyzed for each group. Results: The response rates of the antibiotics-untreated and antibiotics-treated groups with GEM-containing regimens were 15.1% and 27.6%, respectively. The median PFS times of the antibiotics-untreated and antibiotics-treated groups were 2.5 (95% CI: 1.86-3.73) and 4.9 (95% CI: 3.47-6.0) months, respectively. The median OS times of the antibiotics-untreated and antibiotics-treated groups were 7.53 (95% CI: 5.63-9.57) months and 13.83 (95% CI: 10.83-16.43) months, respectively. Conclusion: The addition of antibiotics augments the treatment efficacies of GEM-containing regimens, and it may be a potential therapeutic option to improve treatment efficacies of GEM-containing regimens in patients with advanced cancer.

  37. In Vitro and in Vivo antitumor activity and the mechanism of siphonodictyal B in human colon cancer cells. International-journal Peer-reviewed

    Chikamatsu S, Saijo K, Imai H, Narita K, Kawamura Y, Katoh T, Ishioka C

    Cancer Med　8　(12)　5662-5672　2019

    DOI： 10.1002/cam4.2409 　

    More details Close

    Liphagal, isolated from the marine sponge Aka coralliphaga, exhibits phosphatidylinositol 3-kinase alpha (PI3Kα) inhibitory activity and cytotoxic effects in human cancer cells. Siphonodictyal B, the biogenetic precursor of liphagal, also has PI3K inhibitory activity. However, its cytotoxic or antitumor activities have not been evaluated. In this study, we demonstrated that siphonodictyal B inhibits several kinases such as CDK4/6, CDK7, and PIM2 in addition to PI3K in vitro and that siphonodictyal B exhibits more potent cytotoxic effects than liphagal against human colon cancer cell lines. Furthermore, treatment with siphonodictyal B resulted in increased PARP cleavage, a larger sub-G1 fraction, and a larger annexin V-positive cell population, all of which are indicative of apoptosis induction. As a mechanism of apoptosis induction, we found that siphonodictyal B activates the p38 MAPK pathway, leading the upregulation of proapoptotic factors. Moreover, siphonodictyal B increased ROS levels, thus promoting p38 MAPK pathway activation. NAC, an ROS scavenger, almost completely reversed both the cytotoxic and p38 MAPK pathway-activating effects of siphonodictyal B. These results indicate that the p38 MAPK pathway might be involved downstream of ROS signaling as part of the mechanism of siphonodictyal B-induced apoptosis. Finally, siphonodictyal B displayed antitumor effects in a human colon cancer xenograft mouse model and increased p38 phosphorylation in tumor tissue. These results suggest that siphonodictyal B could serve as the basis of a novel anticancer drug.

  38. Prediction of the three-dimensional structures of histone deacetylase 1 complexed with romidepsin and FK-A5 Peer-reviewed

    A. Oda, K. Kato, M. Morino, T. Nakayoshi, S. Fukuyoshi, K. Saijo, C. Ishioka, E. Kurimoto

    Journal of Physics: Conference Series　1136　(1)　2018/12/24

    DOI： 10.1088/1742-6596/1136/1/012019 　

    ISSN： 1742-6588

    eISSN： 1742-6596

  39. 頭頸部扁平上皮癌患者に対するnivolumabの有効性および安全性に関する後方視的検討

    西條 憲, 梅垣 翔, 高橋 昌宏, 今井 源, 岡田 佳也, 大内 康太, 小峰 啓吾, 佐藤 悠子, 高橋 信, 城田 英和, 高橋 雅信, 石岡 千加史

    日本癌治療学会学術集会抄録集　56回　O54-4　2018/10

    Publisher: (一社)日本癌治療学会

  40. マウスメラノーマモデルにおけるHDAC/PI3K dual inhibitorによる抗PD-1抗体薬の抗腫瘍効果増強の検討(Enhancing efficacy of anti-PD-1 antibody by combination with an HDAC/PI3K dual inhibitor in a mouse model of melanoma)

    西條 憲, 今井 源, 近松 園子, 笠原 佑記, 城田 英和, 加藤 正, 石岡 千加史

    日本癌学会総会記事　77回　474-474　2018/09

    Publisher: (一社)日本癌学会

    ISSN： 0546-0476

  41. Siphonodictoyal Bの大腸癌細胞におけるアポトーシス誘導機序の解析(Mechanism of apoptosis induced by siphonodictoyal B, a derivative of terpenoids in human colon cancer cells)

    近松 園子, 西條 憲, 今井 源, 成田 紘一, 加藤 正, 石岡 千加史

    日本癌学会総会記事　77回　829-829　2018/09

    Publisher: (一社)日本癌学会

    ISSN： 0546-0476

  42. Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors. Peer-reviewed

    Ouchi K, Takahashi S, Chikamatsu S, Ito S, Takahashi Y, Kawai S, Okita A, Kasahara Y, Okada Y, Imai H, Komine K, Saijo K, Takahashi M, Shirota H, Takahashi M, Gamoh M, Ishioka C

    International journal of clinical oncology　23　(4)　790-798　2018/08

    DOI： 10.1007/s10147-018-1261-z 　

    ISSN： 1341-9625

    eISSN： 1437-7772

  43. Efficacy and Safety of Trastuzumab in Combination with S-1 and Cisplatin Therapy for Japanese Patients with HER2-Positive Advanced Gastric Cancer: Retrospective Analysis. Peer-reviewed

    Okita A, Imai H, Takahashi M, Takahashi H, Umegaki S, Kawamura Y, Hiraide S, Ouchi K, Sato Y, Okada Y, Komine K, Saijo K, Takahashi S, Takahashi M, Shirota H, Ohori H, Gamoh M, Ishioka C

    The Tohoku journal of experimental medicine　245　(2)　123-129　2018/06

    DOI： 10.1620/tjem.245.123 　

    ISSN： 0040-8727

    eISSN： 1349-3329

  44. Treatment strategy for sinonasal malignant tumor with skull base invasion Peer-reviewed

    Takenori Ogawa, Ikuho Kojima, Takaki Murata, Maya Sakamoto, Keita Kishida, Noriyoshi Takahashi, Haruo Matsushita, Kazuya Arakawa, Kazuhiro Nomura, Ayako Nakanome, Akira Okoshi, Kenjiro Higashi, Ryo Ishii, Shun Sagai, Keiichi Jingu, Yukio Katori

    Japanese Journal of Head and Neck Cancer　27　(3)　379-385　2018/02

    Publisher: JAPAN SOCIETY FOR HEAD AND NECK SURGERY

    DOI： 10.5106/jjshns.27.379 　

    ISSN： 1349-581X

    eISSN： 1884-474X

  45. Development of a molecular target agent and a biomarker for advanced colorectal cancer Peer-reviewed

    Ishioka Chikashi, Saijo Ken, Takahashi Shin, Ouchi Kota, Imai Hiroo, Takahashi Shin

    CANCER SCIENCE　109　141　2018/01

    ISSN： 1349-7006

  46. Identification and characterization of terpenoid analogues as multi-target kinase inhibitors Peer-reviewed

    Chikamatsu Sonoko, Saijo Ken, Imai Hiroo, Narita Koichi, Katoh Tadashi, Ishioka Chikashi

    CANCER SCIENCE　109　745　2018/01

    ISSN： 1349-7006

  47. Predictive factors for the efficacy of the second taxane treatment in patients with advanced cancer. Cancer Manag Res International-journal Peer-reviewed

    Imai H, Saijo K, Komine K, Kawamura Y, Hiraide S, Umegaki S, Okada Y, Ohuchi K, Sato Y, Takahashi M, Takahashi S, Shirota H, Takahashi M, Ishioka C

    Cancer Manag Res　17　(10)　3629-3636　2018

    DOI： 10.2147/CMAR.S170948 　

    More details Close

    Purpose: Research has revealed that some patients who develop resistance to the first taxane treatment exhibit a moderate response to the second taxane treatment (incomplete cross-resistance between paclitaxel and docetaxel). However, which patients are most likely to respond to the second treatment remains unclear. The aim of this study was to determine the predictive factors for the efficacy of the second taxane treatment in patients resistant to the first. Patients and methods: We enrolled patients treated with paclitaxel and docetaxel (n=31) in this study. Using univariate and multivariate analyses, we determined the predictive factors for the efficacy of the second taxane treatment. Then, we assigned patients to one of the three groups: 1) those with a partial response (PR) to the first taxane treatment who subsequently became refractory (PR group); 2) those whose response was stable disease (SD) and subsequently became refractory (SD group); and 3) those whose response was the progression of the disease with the first taxane treatment (progression disease [PD] group). Furthermore, the response rates were assessed for each group. All statistical analyses were performed using JMP 11. Results: Responses to the first taxane treatment considerably correlated with the efficacy of the second treatment in patients with a PR to the first taxane treatment (P=0.0061, univariate analysis; P=0.0056, multivariate analysis). In addition, response rates to the second taxane treatment in the PR, SD, and PD groups were 33.3%, 0%, and 0%, respectively. Conclusion: The response to the first taxane treatment was a predictive factor for the efficacy of the second taxane treatment in patients with a PR to the first. Thus, the second treatment is highly recommended for patients who exhibit tumor shrinkage (a PR) by the first treatment.

  48. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02) Peer-reviewed

    Tahara M, Kiyota N, Yokota T, Hasegawa Y, Muro K, Takahashi S, Homma A, Taguchi J, Suzuki M, Minato K, Yane K, Ueda S, Hara H, Saijo K, Yamanaka T

    Ann Oncol　29　(4)　1004-1009　2018

  49. IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model Peer-reviewed

    Shuku-ei Ito, Hidekazu Shirota, Yuki Kasahara, Ken Saijo, Chikashi Ishioka

    CANCER IMMUNOLOGY IMMUNOTHERAPY　66　(11)　1485-1496　2017/11

    DOI： 10.1007/s00262-017-2043-6 　

    ISSN： 0340-7004

    eISSN： 1432-0851

  50. Development of an HDAC/PI3K dual inhibitor in academia Peer-reviewed

    Ken Saijo, Chikashi Ishioka

    ANNALS OF ONCOLOGY　28　49-49　2017/10

    ISSN： 0923-7534

    eISSN： 1569-8041

  51. Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3-kinase dual inhibitor Peer-reviewed

    Ken Saijo, Hiroo Imai, Sonoko Chikamatsu, Koichi Narita, Tadashi Katoh, Chikashi Ishioka

    CANCER SCIENCE　108　(7)　1469-1475　2017/07

    DOI： 10.1111/cas.13255 　

    ISSN： 1349-7006

  52. The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: A retrospective, single institutional study Peer-reviewed

    Masahiro Takahashi, Masanobu Takahashi, Keigo Komine, Hideharu Yamada, Yuki Kasahara, Sonoko Chikamatsu, Akira Okita, Shukuei Ito, Kota Ouchi, Yoshinari Okada, Hiroo Imai, Ken Saijo, Hidekazu Shirota, Shin Takahashi, Takahiro Mori, Hideki Shimodaira, Chikashi Ishioka

    PLOS ONE　12　(6)　e0179694　2017/06

    DOI： 10.1371/journal.pone.0179694 　

    ISSN： 1932-6203

  53. Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis Peer-reviewed

    Masanobu Takahashi, Keigo Komine, Hiroo Imai, Yoshinari Okada, Ken Saijo, Masahiro Takahashi, Hidekazu Shirota, Hisatsugu Ohori, Shin Takahashi, Natsuko Chiba, Takahiro Mori, Hideki Shimodaira, Chikashi Ishioka

    PLOS ONE　12　(5)　e0176972　2017/05

    DOI： 10.1371/journal.pone.0176972 　

    ISSN： 1932-6203

  54. Efficacy and safety of denosumab versus zoledronic acid in delaying skeletal-related events in patients with gastrointestinal cancer, pancreasbiliary system cancer, and other rare cancers Peer-reviewed

    Hiroo Imai, Ken Saijo, Hideharu Yamada, Kota Ohuchi, Yoshinari Okada, Keigo Komine, Masahiro Takahashi, Shin Takahashi, Masanobu Takahashi, Hideki Shimodaira, Chikashi Ishioka

    JOURNAL OF BONE ONCOLOGY　6　37-40　2017/03

    DOI： 10.1016/j.jbo.2016.10.002 　

    ISSN： 2212-1366

    eISSN： 2212-1374

  55. Enantioselective Total Synthesis of (-)-Siphonodictyal B and (+)-8-epi-Siphonodictyal B with Phosphatidylinositol 3-Kinase alpha (PI3K alpha) Inhibitory Activity Peer-reviewed

    Takuya Kikuchi, Koichi Narita, Ken Saijo, Chikashi Ishioka, Tadashi Katoh

    EUROPEAN JOURNAL OF ORGANIC CHEMISTRY　(34)　5659-5666　2016/12

    DOI： 10.1002/ejoc.201600949 　

    ISSN： 1434-193X

    eISSN： 1099-0690

  56. Successful sequential treatment of a patient with advanced gastrointestinal stromal tumor using four different molecularly targeted drugs Peer-reviewed

    Sugiyama Shunsuke, Ishizuka Mariko, Takahashi Masanobu, Komine Keigo, Imai Hiroo, Saijo Ken, Takahashi Masahiro, Shirota Hidekazu, Takahashi Shin, Shimodaira Hideki, Ishioka Chikashi

    INTERNATIONAL CANCER CONFERENCE JOURNAL　5　(4)　163-167　2016/10

    DOI： 10.1007/s13691-016-0250-1 　

    ISSN： 2192-3183

  57. Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease Peer-reviewed

    Akihiro Kobayashi, Masanobu Takahashi, Hiroo Imai, Shoko Akiyama, Shunsuke Sugiyama, Keigo Komine, Ken Saijo, Masahiro Takahashi, Shin Takahashi, Hidekazu Shirota, Naomi Sato, Fumiyoshi Fujishima, Taro Shuin, Hideki Shimodaira, Chikashi Ishioka

    INTERNAL MEDICINE　55　(6)　629-634　2016

    DOI： 10.2169/internalmedicine.55.5796 　

    ISSN： 0918-2918

    eISSN： 1349-7235

  58. [Development of biomarkers for molecular target drugs]. Peer-reviewed

    Saijo K, Ishioka C

    Nihon rinsho. Japanese journal of clinical medicine　73　(8)　1308-1312　2015/08

    ISSN： 0047-1852

  59. Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors Peer-reviewed

    Ken Saijo, Jin Imamura, Koichi Narita, Akifumi Oda, Hideki Shimodaira, Tadashi Katoh, Chikashi Ishioka

    CANCER SCIENCE　106　(2)　208-215　2015/02

    DOI： 10.1111/cas.12585 　

    ISSN： 1347-9032

    eISSN： 1349-7006

  60. Efficacy and Safety of Carboplatin and Etoposide Combination Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma: A Retrospective Case Series Peer-reviewed

    Hiroo Imai, Hidekazu Shirota, Akira Okita, Keigo Komine, Ken Saijo, Masahiro Takahashi, Shin Takahashi, Masanobu Takahashi, Hideki Shimodaira, Chikashi Ishioka

    CHEMOTHERAPY　61　(3)　111-116　2015

    DOI： 10.1159/000441551 　

    ISSN： 0009-3157

    eISSN： 1421-9794

  61. Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma Peer-reviewed

    Hiroo Imai, Keigo Komine, Shin Takahashi, Ken Saijo, Yoshinari Okada, Akihiro Kobayashi, Akira Okita, Sonoko Chikamatsu, Yuki Kasahara, Masahiro Takahashi, Takayuki Oishi, Hidekazu Shirota, Masanobu Takahashi, Hideki Shimodaira, Chikashi Ishioka

    CHEMOTHERAPY　61　(5)　262-268　2015

    DOI： 10.1159/000444122 　

    ISSN： 0009-3157

    eISSN： 1421-9794

  62. Predicting the structures of complexes between phosphoinositide 3-kinase (PI3K) and romidepsin-related compounds for the drug design of PI3K/histone deacetylase dual inhibitors using computational docking and the ligand-based drug design approach Peer-reviewed

    Akifumi Oda, Ken Saijo, Chikashi Ishioka, Koichi Narita, Tadashi Katoh, Yurie Watanabe, Shuichi Fukuyoshi, Ohgi Takahashi

    JOURNAL OF MOLECULAR GRAPHICS & MODELLING　54　46-53　2014/11

    DOI： 10.1016/j.jmgm.2014.08.007 　

    ISSN： 1093-3263

    eISSN： 1873-4243

  63. PI3KがHDAC阻害剤ロミデプシンを認識する機構の分子動力学シミュレーションによる解析

    小田 彰史, 西條 憲, 石岡 千加史, 加藤 正, 福吉 修一, 中垣 良一, 高橋 央宜

    日本薬学会年会要旨集　134年会　(2)　296-296　2014/03

    Publisher: (公社)日本薬学会

    ISSN： 0918-9823

  64. Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors Peer-reviewed

    Ken Saijo, Tadashi Katoh, Hideki Shimodaira, Akifumi Oda, Ohgi Takahashi, Chikashi Ishioka

    CANCER SCIENCE　103　(11)　1994-2001　2012/11

    DOI： 10.1111/cas.12002 　

    ISSN： 1347-9032

  65. Identification of romidepsin (FK228) and its analogs as HDAC/PI3K dual inhibitors Peer-reviewed

    Ken Saijo, Tadashi Katoh, Hideki Shimodaira, Akifumi Oda, Ohgi Takahashi, Chikashi Ishioka

    CANCER RESEARCH　72　2012/04

    DOI： 10.1158/1538-7445.AM2012-872 　

    ISSN： 0008-5472

    eISSN： 1538-7445

Show all ︎Show first 5

Misc. 64

  1. Efficacy and safety of DOAC for treatments of VTE in patients undergoing cancer drug treatment

    小峰啓吾, 高橋雅信, 高橋雅信, 岩崎智行, 岩崎智行, 大内康太, 吉田裕也, 吉田裕也, 沼倉龍之助, 沼倉龍之助, 小寺修仁, 小寺修仁, 若山祥之介, 若山祥之介, 植田怜男, 植田怜男, 佐々木啓寿, 佐々木啓寿, 斎藤里佳, 川村佳史, 梅垣翔, 笠原佑記, 笠原佑記, 今井源, 西條憲, 城田英和, 城田英和, 千葉奈津子, 石岡千加史, 石岡千加史, 石岡千加史

    日本臨床腫瘍学会学術集会(CD-ROM)　20th　2023

  2. 同時性四重複癌に対する複数診療科の連携による集学的治療

    江場 俊介, 野津田 泰嗣, 星 史彦, 大石 久, 松田 安史, 佐渡 哲, 野田 雅史, 桜田 晃, 西條 憲, 大越 明, 田中 直樹, 岡田 克典

    胸部外科　72　(9)　655-657　2019/09

    Publisher: (株)南江堂

    ISSN： 0021-5252

  3. Three cases of venous thromboembolism in advanced cancer patients

    Keigo Komine, Masanobu Takahashi, Sakura Hiraide, Sho Umegaki, Yoshifumi Kawamura, Hideharu Yamada, Akira Okita, Sonoko Chikamatsu, Yuki Kasahara, Yoshinari Okada, Hiroo Imai, Ken Saijo, Masahiro Takahashi, Hidekazu Shirota, Chikashi Ishioka

    ANNALS OF ONCOLOGY　29　8-8　2018/10

    ISSN： 0923-7534

    eISSN： 1569-8041

  4. Siphonodictyal Bによる大腸癌細胞のアポトーシス誘導機序の解析

    近松園子, 西條憲, 今井源, 成田紘一, 加藤正, 石岡千加史

    日本がん分子標的治療学会学術集会プログラム・抄録集　22nd　140　2018/04/16

  5. 切除不能進行・再発副腎皮質癌に対するM‐EDP療法の効果と安全に関する後方視的検討

    川村佳史, 西條憲, 今井源, 城田英和, 近松園子, 岡田佳也, 笠原佑記, 梅垣翔, 高橋雅信, 石岡千加史

    日本内科学会雑誌　107　(Suppl.)　270-270　2018/02/20

    Publisher: (一社)日本内科学会

    ISSN： 0021-5384

    eISSN： 1883-2083

  6. 再発または遠隔転移を有する頭頸部癌に対するnivolumabの有効性および安全性に関する検討

    梅垣翔, 高橋信, 平出桜, 沖田啓, 笠原佑記, 大内康太, 西條憲, 高橋昌宏, 高橋雅信, 石岡千加史

    日本内科学会雑誌　107　(Suppl.)　272-272　2018/02/20

    Publisher: (一社)日本内科学会

    ISSN： 0021-5384

  7. 腹膜偽粘液腫8例に対するFOLFOX療法の有効性に関する後方視的解析

    平出桜, 小峰啓吾, 川村佳史, 山田英晴, 沖田啓, 佐藤悠子, 西條憲, 高橋昌宏, 高橋雅信, 石岡千加史

    日本内科学会雑誌　107　(Suppl.)　269-269　2018/02/20

    Publisher: (一社)日本内科学会

    ISSN： 0021-5384

  8. 骨転移を伴う消化器癌及び希少がん患者における、デノスマブとゾレドロン酸の効果比較

    川村 佳史, 今井 源, 西條 憲, 小峰 啓吾, 岡田 佳也, 大内 康太, 山田 英晴, 高橋 昌宏, 高橋 信, 高橋 雅信, 城田 英和, 石岡 千加史

    日本癌治療学会学術集会抄録集　55回　P40-6　2017/10

    Publisher: (一社)日本癌治療学会

  9. 進行・再発尿膜管癌に対しFOLFIRIおよびmFOLFOX6療法を施行した5症例の検討

    平出 桜, 小峰 啓吾, 佐藤 悠子, 大内 康太, 岡田 佳也, 今井 源, 西條 憲, 高橋 昌宏, 高橋 信, 城田 英和, 高橋 雅信, 石岡 千加史

    日本癌治療学会学術集会抄録集　55回　P50-1　2017/10

    Publisher: (一社)日本癌治療学会

  10. がん分子標的治療薬の分子基盤と臨床応用 進行大腸癌の新しい分子標的薬とバイオマーカーの開発

    石岡 千加史, 西條 憲, 高橋 信, 大内 康太, 今井 源, 高橋 雅信

    日本癌学会総会記事　76回　S5-6　2017/09

    Publisher: 日本癌学会

    ISSN： 0546-0476

  11. 多標的キナーゼ阻害薬としてのテルペノイド類化合物の同定とその特徴

    近松 園子, 西條 憲, 今井 源, 成田 紘一, 加藤 正, 石岡 千加史

    日本癌学会総会記事　76回　P-2349　2017/09

    Publisher: 日本癌学会

    ISSN： 0546-0476

  12. 多標的キナーゼ阻害薬としてのテルペノイド類化合物の同定

    近松園子, 西條憲, 成田紘一, 加藤正, 石岡千加史

    日本がん分子標的治療学会学術集会プログラム・抄録集　21st　105　2017/05/17

  13. Efficacy and safety of denosumab versus zoledronic acid in delaying skeletal-related events in patients with gastrointestinal cancer, pancreas-biliary system cancer, and other rare cancers

    Hiroo Imai, Ken Saijo, Hideharu Yamada, Kota Ohuchi, Yoshinari Okada, Keigo Komine, Masahiro Takahashi, Shin Takahashi, Masanobu Takahashi, Hideki Shimodaira, Chikashi Ishioka

    Journal of Bone Oncology　6　37-40　2017/03/01

    Publisher: Elsevier GmbH

    DOI： 10.1016/j.jbo.2016.10.002 　

    ISSN： 2212-1374

  14. 消化器癌及び希少がんの骨転移患者の骨関連事象予防に関するデノスマブとゾレドロン酸の効果比較

    近松 園子, 今井 源, 西條 憲, 小峰 啓吾, 岡田 佳也, 大内 康太, 山田 英晴, 高橋 昌宏, 高橋 雅信, 石岡 千加史

    日本内科学会雑誌　106　(Suppl.)　236-236　2017/02

    Publisher: (一社)日本内科学会

    ISSN： 0021-5384

  15. 消化器癌及び希少がんの骨転移患者の骨関連事象予防に関するデノスマブとゾレドロン酸の効果比較

    近松 園子, 今井 源, 西條 憲, 小峰 啓吾, 岡田 佳也, 大内 康太, 山田 英晴, 高橋 昌宏, 高橋 雅信, 石岡 千加史

    日本内科学会雑誌　106　(Suppl.)　236-236　2017/02

    Publisher: (一社)日本内科学会

    ISSN： 0021-5384

  16. ニボルマブ不応進行悪性黒色腫患者に対するイピリムマブ療法の効果と安全性についての後方視的検討

    西條憲, 近松園子, 大内康太, 岡田佳也, 今井源, 高橋雅信, 城田英和, 下平秀樹, 森隆弘, 石岡千加史

    日本臨床腫瘍学会学術集会(CD-ROM)　15th　ROMBUNNO.P1‐291　2017

  17. HDAC/PI3K二重阻害剤デプシペプチド類化合物のヒト軟部肉腫細胞に対する抗腫瘍効果の評価

    西條 憲, 成田 紘一, 加藤 正, 石岡 千加史

    日本癌学会総会記事　75回　P-2385　2016/10

    Publisher: 日本癌学会

    ISSN： 0546-0476

  18. 膵臓 膵がんに対する化学療法の検討 FOLFIRINOX療法およびGEM+nabPTX療法導入後の進行膵癌患者の生存期間の後ろ向き解析

    近松 園子, 高橋 昌宏, 山田 英晴, 沖田 啓, 小林 輝大, 佐藤 悠子, 大内 康太, 岡田 佳也, 小峰 啓吾, 西條 憲, 今井 源, 高橋 信, 高橋 雅信, 下平 秀樹, 石岡 千加史

    日本癌治療学会学術集会抄録集　54回　WS2-4　2016/10

    Publisher: (一社)日本癌治療学会

  19. HDAC/PI3K二重阻害剤デプシペプチド類化合物のヒト軟部肉腫細胞に対する抗腫瘍効果の評価

    西條 憲, 成田 紘一, 加藤 正, 石岡 千加史

    日本癌学会総会記事　75回　P-2385　2016/10

    Publisher: 日本癌学会

    ISSN： 0546-0476

  20. 膵臓 膵がんに対する化学療法の検討 FOLFIRINOX療法およびGEM+nabPTX療法導入後の進行膵癌患者の生存期間の後ろ向き解析

    近松 園子, 高橋 昌宏, 山田 英晴, 沖田 啓, 小林 輝大, 佐藤 悠子, 大内 康太, 岡田 佳也, 小峰 啓吾, 西條 憲, 今井 源, 高橋 信, 高橋 雅信, 下平 秀樹, 石岡 千加史

    日本癌治療学会学術集会抄録集　54回　WS2-4　2016/10

    Publisher: (一社)日本癌治療学会

  21. 切除不能膵癌におけるGemcitabine、nab-Paclitaxel併用療法の有効性および安全性に関する後方視的検討

    岡田 佳也, 小峰 啓吾, 今井 源, 西條 憲, 高橋 昌宏, 高橋 信, 高橋 雅信, 城田 英和, 下平 秀樹, 石岡 千加史

    日本内科学会雑誌　105　(Suppl.)　233-233　2016/02

    Publisher: (一社)日本内科学会

    ISSN： 0021-5384

  22. 固形がんに合併したDICに対するヒト組換え型トロンボモジュリンの効果(後方視的検討)

    近松 園子, 高橋 信, 伊藤 祝栄, 佐藤 悠子, 大石 隆之, 西條 憲, 高橋 雅信, 石岡 千加史

    日本内科学会雑誌　105　(Suppl.)　273-273　2016/02

    Publisher: (一社)日本内科学会

    ISSN： 0021-5384

  23. 分子標的治療薬の長所と短所 (特集 婦人科がん治療の新機軸)

    西條 憲, 石岡 千加史

    産科と婦人科　83　(1)　63-68　2016/01

    Publisher: 診断と治療社

    ISSN： 0386-9792

  24. 進行骨軟部肉腫に対するゲムシタビン・ドセタキセル併用療法の効果・安全性に関する後方視的解析

    高橋雅信, 高橋雅信, 岡田佳也, 岡田佳也, 小峰啓吾, 小峰啓吾, 今井源, 今井源, 西條憲, 西條憲, 高橋昌宏, 高橋昌宏, 高橋信, 高橋信, 千葉奈津子, 千葉奈津子, 森隆弘, 下平秀樹, 下平秀樹, 石岡千加史, 石岡千加史

    日本臨床腫瘍学会学術集会(CD-ROM)　14th　ROMBUNNO.O1‐11‐5　2016

  25. 切除不能進行再発大腸癌におけるtrifluridine/tipiracil hydrochlorideとregorafenib投与例の効果と安全性に関する後方視的検討

    笠原佑記, 石岡千加史, 下平秀樹, 高橋雅信, 高橋信, 城田秀和, 高橋昌宏, 今井源, 小峰啓吾, 西條憲, 近松園子

    日本臨床腫瘍学会学術集会(CD-ROM)　14th　ROMBUNNO.O1‐8‐4　2016

  26. ヒト軟部肉腫細胞に対するHDAC/PI3K二重阻害剤としてのデプシペプチド類化合物の抗腫瘍効果の検討

    西條憲, 成田紘一, 加藤正, 石岡千加史

    日本がん分子標的治療学会学術集会プログラム・抄録集　20th　176　2016

  27. In vivo antitumor activity of FK-A11, a depsipeptide analog targeting both histone deacetylase and phosphoinositide 3-kinase

    K. Saijo, K. Narita, T. Katoh, C. Ishioka

    ANNALS OF ONCOLOGY　26　2-2　2015/12

    ISSN： 0923-7534

    eISSN： 1569-8041

  28. デプシペプチド類縁体のPI3K阻害剤としての特性に関する検討

    西條 憲, 成田 紘一, 下平 秀樹, 加藤 正, 石岡 千加史

    日本癌学会総会記事　74回　P-3341　2015/10

    Publisher: 日本癌学会

    ISSN： 0546-0476

  29. ドセタキセル耐性食道扁平上皮癌に対するパクリタキセルの効果および安全性の検討

    今井 源, 小峰 啓吾, 西條 憲, 高橋 昌宏, 高橋 信, 高橋 雅信, 石岡 千加史

    日本癌治療学会誌　50　(3)　851-851　2015/09

    Publisher: (一社)日本癌治療学会

    ISSN： 0021-4671

  30. 切除不能進行再発大腸癌に対するregorafenibとTAS102の治療効果に関する後方視的検討

    小峰 啓吾, 小林 輝大, 伊藤 祝栄, 大石 隆之, 岡田 佳也, 今井 源, 西條 憲, 高橋 昌宏, 高橋 雅信, 高橋 信, 城田 英和, 千葉 奈津子, 下平 秀樹, 森 隆弘, 石岡 千加史

    日本癌治療学会誌　50　(3)　2417-2417　2015/09

    Publisher: (一社)日本癌治療学会

    ISSN： 0021-4671

  31. 東北大学病院腫瘍内科における神経内分泌癌への白金製剤+エトポシド併用療法の検討

    沖田 啓, 今井 源, 笠原 佑記, 近松 園子, 大石 隆之, 岡田 佳也, 小峰 啓吾, 西條 憲, 高橋 昌宏, 高橋 信, 高橋 雅信, 城田 英和, 下平 秀樹, 石岡 千加史

    日本癌治療学会誌　50　(3)　2559-2559　2015/09

    Publisher: (一社)日本癌治療学会

    ISSN： 0021-4671

  32. 【固形がんの分子標的薬-基礎研究から創薬・開発・臨床まで-】 がん分子標的治療の臨床 分子標的治療薬とバイオマーカー開発

    西條 憲, 石岡 千加史

    日本臨床　73　(8)　1308-1312　2015/08

    Publisher: (株)日本臨床社

    ISSN： 0047-1852

  33. 乳癌および甲状腺腫術後に胃癌を発症したCowden病の1例

    下平 秀樹, 河合 貞幸, 高橋 雅信, 今井 源, 西條 憲, 小峰 啓吾, 高橋 信, 石岡 千加史

    家族性腫瘍　15　(2)　A95-A95　2015/05

    Publisher: 日本家族性腫瘍学会

    ISSN： 1346-1052

  34. 東北大学腫瘍内科における消化管間質腫瘍(GIST)に対する分子標的治療後の効果と安全性に関する後方視的解析

    杉山 俊輔, 小峰 啓吾, 今井 源, 西條 憲, 高橋 昌宏, 城田 英和, 高橋 信, 高橋 雅信, 下平 秀樹, 石岡 千加史

    日本内科学会雑誌　104　(Suppl.)　142-142　2015/02

    Publisher: (一社)日本内科学会

    ISSN： 0021-5384

  35. 進行再発胆道癌におけるゲムシタビン+シスプラチン(GEM+CDDP)併用療法の治療効果と安全性

    下平 秀樹, 杉山 俊輔, 高橋 雅信, 小峰 啓吾, 西條 憲, 今井 源, 城田 英和, 高橋 昌宏, 高橋 信, 石岡 千加史

    日本内科学会雑誌　104　(Suppl.)　142-142　2015/02

    Publisher: (一社)日本内科学会

    ISSN： 0021-5384

  36. 東北大学病院腫瘍内科における肺外神経内分泌癌(NEC)に対する化学療法の後方視的解析

    今井 源, 小林 輝大, 城田 英和, 杉山 俊輔, 小峰 啓吾, 高橋 昌宏, 西條 憲, 高橋 信, 高橋 雅信, 石岡 千加史

    日本内科学会雑誌　104　(Suppl.)　238-238　2015/02

    Publisher: (一社)日本内科学会

    ISSN： 0021-5384

  37. 治癒切除不能進行膵癌11症例に対するFOLFIRINOX療法の有効性と安全性に関する後方視的検討

    小林 輝大, 高橋 雅信, 杉山 俊輔, 小峰 啓吾, 西條 憲, 今井 源, 高橋 信, 城田 英和, 下平 秀樹, 石岡 千加史

    日本内科学会雑誌　104　(Suppl.)　283-283　2015/02

    Publisher: (一社)日本内科学会

    ISSN： 0021-5384

  38. 小腸癌に対する5FU系薬剤による治療成績の後方視的解析

    今井源, 西條憲, 小峰啓吾, 小林輝大, 高橋信, 高橋雅信, 城田英和, 高橋昌宏, 石岡千加史

    日本臨床腫瘍学会学術集会(CD-ROM)　13th　ROMBUNNO.P2-8-6　2015

  39. 軟部肉腫に対するドキソルビシン+イホスファマイド併用療法の治療成績についての後方視的検討

    西條憲, 西條憲, 伊藤祝栄, 伊藤祝栄, 小峰啓吾, 小峰啓吾, 今井源, 今井源, 城田英和, 城田英和, 高橋昌宏, 高橋昌宏, 高橋信, 高橋信, 高橋雅信, 高橋雅信, 下平秀樹, 下平秀樹, 石岡千加史, 石岡千加史

    日本臨床腫瘍学会学術集会(CD-ROM)　13th　ROMBUNNO.P3-9-58　2015

  40. 治癒切除不能進行膵癌におけるFOLFIRINOX療法の有効性および安全性に関する後方視的検討

    小林輝大, 小林輝大, 高橋雅信, 杉山俊輔, 西條憲, 今井源, 高橋昌宏, 高橋信, 城田英和, 下平秀樹, 下平秀樹, 石岡千加史, 石岡千加史

    日本臨床腫瘍学会学術集会(CD-ROM)　13th　ROMBUNNO.P1-8-10　2015

  41. 新規HDAC/PI3K 2重阻害剤としてのデプシペプチド類縁体の抗腫瘍活性の検討(In vivo antitumor activity of romidepsin analogs as novel HDAC/PI3K dual inhibitors)

    西條 憲, 李 仁, 成田 紘一, 加藤 正, 下平 秀樹, 石岡 千加史

    日本癌学会総会記事　73回　P-3356　2014/09

    Publisher: 日本癌学会

    ISSN： 0546-0476

  42. 骨転移を有する進行癌35例に対するデノスマブの有効性と安全性に関する後ろ向き解析

    佐藤 悠子, 西條 憲, 井上 正広, 添田 大司, 坂本 康寛, 塩野 雅俊, 高橋 雅信, 高橋 信, 角道 祐一, 城田 英和, 秋山 聖子, 下平 秀樹, 森 隆弘, 加藤 俊介, 石岡 千加史

    日本癌治療学会誌　49　(3)　2124-2124　2014/06

    Publisher: (一社)日本癌治療学会

    ISSN： 0021-4671

  43. 進行再発胆道癌におけるゲムシタビン+シスプラチン併用療法の治療効果と安全性

    下平 秀樹, 高橋 信, 高橋 雅信, 高橋 昌宏, 西條 憲, 城田 英和, 小峰 啓吾, 今井 源, 森 隆弘, 石岡 千加史

    日本癌治療学会誌　49　(3)　1348-1348　2014/06

    Publisher: (一社)日本癌治療学会

    ISSN： 0021-4671

  44. 家族性大腸腫瘍 進行大腸癌に対する化学療法を行ったLynch症候群疑いの4例

    下平 秀樹, 高橋 雅信, 西條 憲, 小峰 啓吾, 今井 源, 杉山 俊輔, 高橋 昌宏, 城田 英和, 高橋 信, 森 隆弘, 石岡 千加史

    家族性腫瘍　14　(2)　A25-A25　2014/05

    Publisher: 日本家族性腫瘍学会

    ISSN： 1346-1052

  45. 東北大学病院におけるがん診療に関わる診療科横断的カンファレンスの実績と課題

    下平 秀樹, 添田 大司, 高橋 秀和, 伊藤 祝栄, 西條 憲, 小峰 啓吾, 李 仁, 高橋 雅信, 加藤 俊介, 石岡 千加史

    日本内科学会雑誌　103　(Suppl.)　250-250　2014/02

    Publisher: (一社)日本内科学会

    ISSN： 0021-5384

  46. HDAC/PI3K dual inhibitorとしてのFK228類縁体の同定と開発

    西條憲, 李仁, 加藤正, 小田彰史, 下平秀樹, 石岡千加史

    がん研究分野の特性等を踏まえた支援活動公開シンポジウムプログラム・抄録集 平成25年度　52　2014

  47. L-OHP間歇投与法による蓄積性末梢神経障害の改善効果の検討(T-CORE0901試験)

    加藤 俊介, 蒲生 真紀夫, 進藤 吉明, 角道 祐一, 安田 勝洋, 塩野 雅俊, 黒木 実智雄, 西條 憲, 大堀 久詔, 横山 直弘, 高畑 武功, 酒寄 真人, 菅谷 明徳, 吉岡 孝志, 石岡 千加史

    日本癌治療学会誌　48　(3)　1397-1397　2013/09

    Publisher: (一社)日本癌治療学会

    ISSN： 0021-4671

  48. 大腸癌におけるEGFR関連遺伝子解析とその抗EGFR抗体薬に対する効果予測マーカーとしての有用性

    下平秀樹, 添田大司, 渡辺みか, 小峰啓吾, 西條憲, 井上正広, 高橋信, 鈴木貴夫, 蒲生真紀夫, 加藤俊介, 石岡千加史

    日本がん分子標的治療学会学術集会プログラム・抄録集　17th　72　2013/05/31

  49. HDAC/PI3K dual inhibitorとしてのRomidepsin(FK228)新規類縁体の開発と最適化

    LEE Jin, 西條憲, 下平秀樹, 成田紘一, 加藤正, 石岡千加史

    日本がん分子標的治療学会学術集会プログラム・抄録集　17th　92　2013/05/31

  50. 神経線維腫症1型に併発した悪性腫瘍に対し化学療法を行った5例

    下平 秀樹, 西條 憲, 添田 大司, 井上 正広, 塩野 雅俊, 城田 英和, 高橋 信, 高橋 雅信, 加藤 俊介, 石岡 千加史

    家族性腫瘍　13　(2)　A75-A75　2013/05

    Publisher: 日本家族性腫瘍学会

    ISSN： 1346-1052

  51. 神経線維腫症1型に併発した悪性末梢神経鞘腫瘍に対し化学療法を行った3例

    下平秀樹, 西條憲, 大内康太, 高橋秀和, 吉野優樹, 李仁, 佐藤悠子, 塩野雅俊, 加藤俊介, 石岡千加史

    日本内科学会雑誌　102　243　2013/02/20

    ISSN： 0021-5384

  52. 軟部肉腫に対するADM+IFM併用療法の治療成績に関する後方視的検討

    西條 憲, 大内 康太, 高橋 秀和, 角道 祐一, 高橋 信, 高橋 雅信, 添田 大司, 李 仁, 加藤 俊介, 石岡 千加史

    日本内科学会雑誌　102　(Suppl.)　196-196　2013/02

    Publisher: (一社)日本内科学会

    ISSN： 0021-5384

  53. 骨転移を有する進行癌患者に対するデノスマブ療法による低Ca血症の発現リスク関する後方視的解析

    佐藤悠子, 加藤俊介, 木皿重樹, 角道祐一, 高橋雅信, 秋山聖子, 添田大司, 西條憲, 井上正広, 石岡千加史

    日本臨床腫瘍学会学術集会(CD-ROM)　11th　ROMBUNNO.P1-030　2013

  54. 進行大腸癌に対する化学療法を行ったLynch症候群の5例

    下平 秀樹, 高橋 雅信, 西條 憲, 塩野 雅俊, 添田 大司, 井上 正広, 秋山 聖子, 高橋 信, 角道 祐一, 森 隆弘, 加藤 俊介, 石岡 千加史

    家族性腫瘍　12　(2)　A34-A34　2012/05

    Publisher: 日本家族性腫瘍学会

    ISSN： 1346-1052

  55. 進行再発大腸癌においてセツキシマブ不応後にパニツムマブを施行した治療成績

    李仁, 加藤俊介, 高橋昌宏, 高橋秀和, 大内康太, 吉野優樹, 大石隆之, 斎藤菜穂子, 杉山俊輔, 岡田佳也, 小峰啓吾, 西條憲, 河合貞幸, 井上正広, 今井源, 塩野雅俊, 吉田こず恵, 秋山聖子, 高橋信, 角道祐一, 下平秀樹, 森隆弘, 石岡千加史

    東北医学雑誌　123　(2)　210　2011/12/25

    ISSN： 0040-8700

  56. 出芽酵母を用いた新規PI3K阻害剤のスクリーニング(Screening for novel PI3K inhibitors by using Saccharomyces cerevisiae)

    西條 憲, 下平 秀樹, 加藤 正, 石岡 千加史

    日本癌学会総会記事　70回　181-181　2011/09

    Publisher: 日本癌学会

    ISSN： 0546-0476

  57. 【見逃してはいけない家族性腫瘍】 見逃してはいけない家族性腫瘍 内科領域で見落としやすい家族性腫瘍

    下平 秀樹, 西條 憲, 添田 大司, 小峰 啓吾, 高橋 雅信, 石岡 千加史

    家族性腫瘍　11　(1)　19-22　2011/01

    Publisher: 日本家族性腫瘍学会

    ISSN： 1346-1052

  58. 見逃してはいけない家族性腫瘍 内科領域で見落としやすい家族性腫瘍

    下平 秀樹, 西條 憲, 石岡 千加史

    家族性腫瘍　10　(2)　A29-A29　2010/05

    Publisher: 日本家族性腫瘍学会

    ISSN： 1346-1052

  59. 家族性大腸癌の遺伝子解析と臨床像

    下平秀樹, 高橋雅信, 西條憲, 添田大司, 小峰啓吾, 石岡千加史

    日本内科学会雑誌　99　247　2010/02/20

    ISSN： 0021-5384

  60. 3次治療以降でセツキシマブ、イリノテカン併用療法が奏効したKRAS野生型進行直腸癌の2症例

    西條 憲, 加藤 俊介, 森 隆弘, 下平 秀樹, 秋山 聖子, 角道 祐一, 高橋 信, 大堀 久詔, 高橋 雅信, 坂本 康寛, 高橋 昌宏, 添田 大司, 工藤 千枝子, 井上 正広, 今井 源, 河合 貞幸, 小峰 啓吾, 岡田 佳也, 石岡 千加史

    東北医学雑誌　121　(2)　200-200　2009/12

    Publisher: 東北医学会

    ISSN： 0040-8700

  61. 当科におけるGIST治療の検討

    小峰 啓吾, 大塚 和令, 加藤 俊介, 森 隆弘, 下平 秀樹, 角道 祐一, 高橋 信, 高橋 雅信, 大堀 久詔, 西條 憲, 今井 源, 井上 正広, 河合 貞幸, 石岡 千加史

    日本癌治療学会誌　44　(2)　828-828　2009/09

    Publisher: (一社)日本癌治療学会

    ISSN： 0021-4671

  62. 当科におけるFOLFOX・FOLFIRI療法施行大腸癌症例に対するS‐1単剤投与治療成績

    今井源, 加藤俊介, 柴田浩行, 下平秀樹, 大塚和令, 角道祐一, 大堀久詔, 高橋信, 高橋雅信, 坂本康寛, 高橋昌宏, 添田大司, 工藤千枝子, 西條憲, 井上正広, 河合貞幸, 小峰啓吾, 石岡千加史

    東北医学雑誌　120　(2)　200　2008/12/25

    ISSN： 0040-8700

  63. Bevacizumab投与後に発症した消化管穿孔5症例の検討

    高橋昌宏, 加藤俊介, 柴田浩行, 森隆弘, 下平秀樹, 大塚和令, 角道祐一, 高橋信, 大堀久詔, 高橋雅信, 坂本康寛, 添田大司, 工藤千枝子, 井上正広, 今井源, 河合貞幸, 小峰啓吾, 西條憲, 石岡千加史

    日本癌治療学会誌　43　(2)　862　2008/10/01

    ISSN： 0021-4671

  64. 進行再発大腸癌化学療法の進歩―自施設症例の後ろ向き研究

    高橋信, 大塚和令, 大堀久詔, 高橋雅信, 坂本康寛, 高橋昌宏, 添田大司, 工藤千枝子, 今井源, 河合貞幸, 小峰啓吾, 井上正広, 西條憲, 角道祐一, 下平秀樹, 加藤俊介, 森隆弘, 柴田浩行, 石岡千加史

    日本癌治療学会誌　43　(2)　612　2008/10/01

    ISSN： 0021-4671

Show all ︎Show first 5

Books and Other Publications 4

  1. 産科と婦人科 83

    西條 憲

    2016

  2. 抗がん剤の副作用と支持療法

    西條 憲

    日本臨床　2015

  3. 日本臨床 73

    西條 憲

    2015

  4. モダンフィジシャン

    西條 憲

    新興医学出版社　2013

Industrial Property Rights 2

  1. リファガールの類縁体、及びリファガール又はその類縁体を含む多標的キナーゼ阻害剤

    Property Type: Patent

    Holder: 西條 憲, 石岡 千加史, 加藤 正, 成田 紘一

  2. 新規ホスファチジルイノシトール３キナーゼ阻害剤及び医薬組成物

    西條 憲

    特許6214397

    Property Type: Patent

Research Projects 10

  1. DNAメチル化状態に基づいた頭頸部癌薬物療法のバイオマーカー開発

    西條 憲, 大内 康太

    Offer Organization: 日本学術振興会

    System: 科学研究費助成事業

    Category: 基盤研究(C)

    Institution: 東北大学

    2024/04 - 2027/03

  2. 抗がん活性と抗菌活性を保有する新規ナノ粒子製剤の開発

    小関良卓

    Offer Organization: 物質・デバイス領域共同研究拠点

    System: 共同研究課題

    Category: 基盤共同研究

    Institution: 東北大学

    2024/04 - 2025/03

  3. 抗腫瘍効果の増強を目的とした抗がん薬と抗菌薬のナノ粒子配合薬の開発

    西條憲, 今井源, 笠井均, 小関良卓

    Offer Organization: 日本医療研究開発機構

    System: 橋渡し研究プログラム

    Category: 異分野融合型研究開発推進事業 シーズA

    Institution: 東北大学

    2024/04 - 2025/03

  4. 甲状腺未分化癌に対する新規治療法および治療薬の開発 Competitive

    西條 憲

    Offer Organization: 科研費

    System: 科学研究費助成事業（基盤C）

    2017/04 - 2020/03

  5. HDAC/PI3K二重阻害活性を有する新規デプシペプチド類縁体の開発 Competitive

    石岡千加史

    Offer Organization: 日本医療研究開発機構

    System: 橋渡し研究加速ネットワークプログラム シーズB

    2018/04 - 2019/03

  6. 悪性末梢神経鞘腫に対する新規治療薬の開発 Competitive

    西條 憲

    Offer Organization: 科研費

    System: 科学研究費助成事業（若手研究B）

    2015/04 - 2017/03

  7. HDAC/PI3K二重阻害活性を有する新規デプシペプチド類縁体の開発 Competitive

    石岡千加史

    Offer Organization: 日本医療研究開発機構

    System: 橋渡し研究加速ネットワークプログラムシーズB

    2014/04 - 2017/03

  8. A search and optimization of the novel cancer molecules target drugs with PI3K/HDAC dual inhibition

    ISHIOKA Chikashi, KATO Tadashi, SAIJO Ken, LI Jin

    Offer Organization: Japan Society for the Promotion of Science

    System: Grants-in-Aid for Scientific Research

    Category: Grant-in-Aid for Scientific Research (B)

    Institution: Tohoku University

    2012/04/01 - 2015/03/31

    More details Close

    Novel FK228 analogs as PI3K/HDAC dual inhibitors were synthesized, and, by docking simulation of a new analog and PI3K catalytic subunit p100α, and an evaluation of the PI3K inhibitory activity, we synthesized new analog FK-A11 which was stronger PI3K inhibitory activity than FK228 and its analog FK-A5. We found that the novel FK228 analogs with the strong PI3K inhibitory activity had inhibitory activities on both the apoptotic induction and intracellular signal transduction and strongly suggested that the PI3K inhibitory activity correlated with antitumor effect of the compounds. We also found that the novel FK228 analog was effective against prostate cancer and colorectal cancer, particularly effective in colorectal cancer cells with the KRAS gene mutation refractory to anti-EGFR antibody, a molecular target drug. Also, we found that FK-A11 was a pan-PI3K inhibitor and an ATP-competitive inhibitor.

  9. 新規HDAC/PI3K dual inhibitorの開発 Competitive

    西條 憲

    Offer Organization: 科研費

    System: 科学研究費助成事業（若手研究B）

    2013/04 - 2015/03

  10. HADC/PI3K 2重阻害剤の開発 Competitive

    西條 憲

    Offer Organization: 東北大学艮陵医学振興会

    System: 医学研究助成金

    2013/04 - 2014/03

Show all Show first 5

Teaching Experience 2

  1. 臨床薬理学 がん薬物療法概論・各論　東北大学薬学部

  2. 臨床腫瘍学総論・各論　東北大学医学部